Иммунопрофилактика респираторно-синцитиальной вирусной инфекции у младенцев с бронхолегочной дисплазией (Окончание. Начало в № 4 за 2010 год)

Immunoprophylaxis of respiratory syncytial virus infection in infants with bronchopulmonary dysplasia. (Conclusion. The beginning in № 4 for 2010)

The review contains information about contribution of respirtory syncytial virus (RSV) into development of acute states of bronchopulmonary dysplasia (BPD). An innovative highly-effectively method of prevention of RSV- infection in infants with BPD is described by means of monoclonal antibody drug -рalivizumab. General data on a new class of immuno-stimulating therapy - humanized target-specific monoclonal antibody are presented. Immunobyological characteristics, mechanism of action, farmacokinetics and effectiveness of рalivizumab in patients with BPD are also described.